Condition: Acute Myeloid Leukemia · Leukemia · Sponsor: Daiichi Sankyo
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
This description comes directly from the study's public registry record.
Contact for Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| John Hopkins School of Medicine | Baltimore, Maryland, United States | Not Yet Recruiting |
| Umass Memorial Health Care Systems | Worcester, Massachusetts, United States | Withdrawn |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Withdrawn |
| Weill Cornell | New York, New York, United States | Not Yet Recruiting |
| Westchester Medical College | Valhalla, New York, United States | Withdrawn |
| Clinical Research Allicance | Westbury, New York, United States | Not Yet Recruiting |
| Spoknwrd Clinical Trials Inc. | Easton, Pennsylvania, United States | Recruiting |
| The Methodist Hospital Research Institute | Houston, Texas, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Royal Adelaide Hospital | Adelaide, Australia | Not Yet Recruiting |
| Austin Health | Australia, Australia | Recruiting |
| St. Vincent's Hospital Melbourne | Darlinghurst, Australia | Recruiting |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06824168